SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like Dexcom Launches Direct-to-Watch: G7 Now Connects Directly with Apple Watch in U.S. June 22, 2024 Does air pollution drive dementia? September 4, 2024 New ‘Doctor Who’ festive episodes associated with lower UK death rates December 18, 2023